drugset / Trial / NCT04519151
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.
Timeline
- Start
- 2021-04-12
- Primary completion
- 2023-11
- Completion
- 2029-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 20 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |